These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17957142)

  • 1. Modulation of the p53-MDM2 interaction by phosphorylation of Thr18: a computational study.
    Lee HJ; Srinivasan D; Coomber D; Lane DP; Verma CS
    Cell Cycle; 2007 Nov; 6(21):2604-11. PubMed ID: 17957142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetic and thermodynamic effects of phosphorylation on p53 binding to MDM2.
    Yadahalli S; Neira JL; Johnson CM; Tan YS; Rowling PJE; Chattopadhyay A; Verma CS; Itzhaki LS
    Sci Rep; 2019 Jan; 9(1):693. PubMed ID: 30679555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21.
    Jabbur JR; Tabor AD; Cheng X; Wang H; Uesugi M; Lozano G; Zhang W
    Oncogene; 2002 Oct; 21(46):7100-13. PubMed ID: 12370832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The electrostatic surface of MDM2 modulates the specificity of its interaction with phosphorylated and unphosphorylated p53 peptides.
    Brown CJ; Srinivasan D; Jun LH; Coomber D; Verma CS; Lane DP
    Cell Cycle; 2008 Mar; 7(5):608-10. PubMed ID: 18256546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
    Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
    Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A spatiotemporal characterization of the effect of p53 phosphorylation on its interaction with MDM2.
    ElSawy KM; Sim A; Lane DP; Verma CS; Caves LS
    Cell Cycle; 2015; 14(2):179-88. PubMed ID: 25584963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2.
    Teufel DP; Bycroft M; Fersht AR
    Oncogene; 2009 May; 28(20):2112-8. PubMed ID: 19363523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thermodynamic and computational studies on the binding of p53-derived peptides and peptidomimetic inhibitors to HDM2.
    Grässlin A; Amoreira C; Baldridge KK; Robinson JA
    Chembiochem; 2009 May; 10(8):1360-8. PubMed ID: 19408261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 Antiproliferative function is enhanced by aspartate substitution at threonine 18 and serine 20.
    Jabbur JR; Zhang W
    Cancer Biol Ther; 2002; 1(3):277-83. PubMed ID: 12432277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 Phosphomimetics Preserve Transient Secondary Structure but Reduce Binding to Mdm2 and MdmX.
    Levy R; Gregory E; Borcherds W; Daughdrill G
    Biomolecules; 2019 Mar; 9(3):. PubMed ID: 30832340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of p53: How phosphorylated Ser15 triggers sequential phosphorylation of p53 at Thr18 by CK1δ.
    Nicolaou ST; Kannan S; Warwicker J; Verma CS
    Proteins; 2022 Dec; 90(12):2009-2022. PubMed ID: 35752942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2-binding motif of p53.
    Zondlo SC; Lee AE; Zondlo NJ
    Biochemistry; 2006 Oct; 45(39):11945-57. PubMed ID: 17002294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of p53-dependent transcription by BOX-I phospho-peptide mimetics that bind to p300.
    Dornan D; Hupp TR
    EMBO Rep; 2001 Feb; 2(2):139-44. PubMed ID: 11258706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct observations of conformational distributions of intrinsically disordered p53 peptides using UV Raman and explicit solvent simulations.
    Xiong K; Zwier MC; Myshakina NS; Burger VM; Asher SA; Chong LT
    J Phys Chem A; 2011 Sep; 115(34):9520-7. PubMed ID: 21528875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of MDM2 binding to p53-analogues: affinity, helicity, and applicability to drug design.
    Kalid O; Ben-Tal N
    J Chem Inf Model; 2009 Apr; 49(4):865-76. PubMed ID: 19323449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100.
    Dastidar SG; Lane DP; Verma CS
    BMC Bioinformatics; 2009 Dec; 10 Suppl 15(Suppl 15):S6. PubMed ID: 19958516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening of medicinal plant phytochemicals as natural antagonists of p53-MDM2 interaction to reactivate p53 functioning.
    Riaz M; Ashfaq UA; Qasim M; Yasmeen E; Ul Qamar MT; Anwar F
    Anticancer Drugs; 2017 Oct; 28(9):1032-1038. PubMed ID: 28723868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers.
    Craig AL; Burch L; Vojtesek B; Mikutowska J; Thompson A; Hupp TR
    Biochem J; 1999 Aug; 342 ( Pt 1)(Pt 1):133-41. PubMed ID: 10432310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PML enhances the regulation of p53 by CK1 in response to DNA damage.
    Alsheich-Bartok O; Haupt S; Alkalay-Snir I; Saito S; Appella E; Haupt Y
    Oncogene; 2008 Jun; 27(26):3653-61. PubMed ID: 18246126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of a novel MDM2 binding peptide based on the p53 family.
    Madhumalar A; Lee HJ; Brown CJ; Lane D; Verma C
    Cell Cycle; 2009 Sep; 8(17):2828-36. PubMed ID: 19713735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.